Redeye sees a Q1 report from Genovis largely aligning with our estimates with minor deviation on the downside for sales and upside for EBIT. The share currently slightly above our bear case, but for how long?

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

GenovisQ1 2024 - Financials in line with expectations, strong outlook

© Modular Finance, source Nordic Press Releases